Bibliography

ESMO 2024: Prof. Reichardt

• Benjamin RS, et al. Cancer. 1974;33(1):19–27.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Joensuu H, et al. N Engl J Med. 2001;344(14):1052–1056.
• Maki RG, et al. Int J Cancer. 2002;100(6):623–626.
• van der Graaf WT, et al. Lancet. 2012;379(9829):1879–1886.

ESMO 2024: Dr Gronchi

• Bellefkih FZ, et al. Cancer/Radiothérapie. 2023;27:622–637.
• Calderillo-Ruíz G, et al. Neoplasia. 2024;48:100959.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Fairweather M, et al. Ann Surg. 2018;268(2):296–302.
• Gelderblom H, et al. J Clin Oncol. 2023;41(16 suppl):11585.
• Gruber L, et al. Biomedicines. 2022;10(11):2899.
• Joensuu H, et al. Lancet Oncol. 2012;13(3):265–274.
• Mastboom MJL, et al. Acta Orthop. 2017;88(6):688–694.
• Mastboom MJL, et al. Lancet Oncol. 2019;20:877–886.
• Nishida T, et al. Cancer. 2016;122(20):3110–3118.
• Rathmann N, et al. J Vasc Interv Radiol. 2015;26:231–238.
• Schipani A, et al. Genes. 2023;14:646–662.
• Serrano C, et al. Ther Adv Med Oncol. 2023;15:17588359231192388.
• Stacchiotti S, et al. Cancer Treat Rev. 2023;112:102491.

ESMO 2024: Prof. Gelderblom

• Blay JY, et al. Ann Oncol. 2008;19(4):821–822.
• Brooke B, et al. Drug Des Devel Ther. 2020;14:1693–1704.
• Cassier PA, et al. Cancer. 2012;118(6):1649–1655.
• ClinicalTrials.gov. NCT04731675.
• ClinicalTrials.gov. NCT05417789.
• ClinicalTrials.gov. NCT05804045.
• Gelderblom H, et al. Lancet Oncol. 2018;19(5):639–648.
• Mastboom MJL, et al. Acta Orthop. 2017;88(6):688–694.
• Mastboom MJL, et al. Interact J Med Res. 2018;7(1):e4.
• Mastboom MJL, et al. Lancet Oncol. 2019;20:877–886.
• Spierenburg G, et al. Eur J Cancer. 2022;173:219–228.
• Tap WD, et al. Future Oncol. 2024;20(10):593–601.
• Tap WD, et al. Lancet. 2019;394(10197):478–487.
• TURALIO Prescribing Information. November 2023.
• Verspoor FGM, et al. Sci Rep. 2019;9:14551.
• West RB, et al. Proc Natl Acad Sci USA. 2006;103(3):690–695.

ESMO 2024: Prof. Le Cesne

• Bauer S, et al. Front Oncol. 2021;11:672500.
• Bauer S, et al. J Clin Oncol. 2022;40(34):3918–3928.
• Bauer S, et al. J Clin Oncol. 2022;40(34):3918–3928 (Suppl).
• Bauer S, et al. J Clin Oncol. 2023;41(suppl 36). Abstr 397784.
• Blanke C, et al. J Clin Oncol. 2008;26(4):620–625.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• ClinicalTrials.gov. NCT03556384.
• ClinicalTrials.gov. NCT04193553.
• ClinicalTrials.gov. NCT04936178.
• ClinicalTrials.gov. NCT05152472.
• ClinicalTrials.gov. NCT05208047.
• Cousin S, et al. Presented at: ESMO 2023. Abstract 1920MO.
• Demetri GD, et al. Lancet. 2006;368(9544):1329–1338.
• Demetri GD, et al. Lancet. 2013;381(9863):295–302.
• George S, et al. Presented at ASCO 2023. Abstract TPS11582.
• Heinrich M, et al. JAMA Oncol. 2017;3(7):944–952.
• Heinrich M, et al. Lancet Oncol. 2020;21(7):935–946.
• Heinrich M, et al. Nat Med. 2024; doi: https://doi.org/10.1038/s41591-023-02734-5.
• Janeway KA, et al. Pediatr Blood Cancer. 2009;52(7):767–771.
• Kang YK, et al. J Clin Oncol. 2021;39(28):3128–3139.
• Le Cesne A, et al. Lancet Oncol. 2010;11(10):942–949.
• Martin-Broto J, et al. Mol Cancer. 2023;22(1):127.
• Mohammadi M, Gelderblom H. Expert Opin Investig Drugs. 2021;30(2):143–152.
• Patrikidou A, et al. Eur J Cancer. 2016;52:173–180.
• QINLOCK Summary of Product Characteristics 2023.
• Qiu H, ASCO J Clin Oncol. 2022;40(16):11513.
• Salem ME, et al. Mol Cancer Res. 2018;16(5):805–812.
• Singh AS, et al. Clin Cancer Res. 2022;28:84–94.
• Smith B, et al. Cancer Cell. 2019;35(5):738–751.
• STIVARGA Summary of Product Characteristics 2023.
• SUTENT Summary of Product Characteristics 2021.
• Tap WD, et al. Oral presentation at ASCO 2023.
• Vallilas C, et al. Int J Med Sci. 2021;22(2):493.
• Verma S, et al. Fur Sci OA. 2021; FSO676.
• Verweij J, et al. Lancet. 2004;364(9440):1127–1134.
• Yeh CN, et al. Oncotarget. 2017;8(27):44121–44130.

ESMO 2023: Dr Napolitano

• Blanke CD, et al. Clin Oncol. 2008;26(4):626–632.
• Blay JY, et al. Nat Rev Dis Primers. 2021;7(1):22.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Demetri GD, et al. N Engl J Med. 2002;347(7):472–480.
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). J Clin Oncol. 2010;28(7):1247–1253.
• Grant G. Brain Res Rev. 2007;55:490–498.
• Heinrich MC, et al. Clin Sarcoma Res. 2019;9:3.
• Hirota S, et al. Science. 1998;279(5350):577–580.
• Joensuu H, et al. N Engl J Med. 2001;344(14):1052–1056.
• Joensuu H. Hum Pathol. 2008;39(10):1411–1419.
• Joensuu H, et al. JAMA Oncol. 2020;6(8):1241–1246.
• Klug LR, et al. Nat Rev Clin Oncol. 2022;19(5):328–341.
• Mostafa RM, et al. World J Gastroenterol. 2010;16(26):3239–3248.
• Serrano C, et al. Br J Cancer. 2019;120:612–620.
• TIME. Drugs that fight cancer. 28 May 2001 [Cover]. Available at https://content.time.com/time/covers/0,16641,20010528,00.html Accessed September 2023.
• van Oosterom AT, et al. Lancet. 2001;358(9291):1421–1423.
• Verweij J, et al. Lancet. 2004;364(9440):1127–1134.
• Vincenzi B, et al. Clin Cancer Res. 2022;28(8):1672–1679.

ESMO 2023: Dr Watson

• Bauer S, et al. Front Oncol. 2021;11:672500.
• Bauer S, et al. Presented at the American Society of Clinical Oncology Plenary Series; 24 January 2023; Online.
• Blay JY, et al. Lancet. 2020;21(7):923–934.
• Blay JY, et al. Nat Rev Dis Primers. 2021;7:22.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Cohen P, et al. Nat Rev Drug Discov. 2021;20:551–569.
• Demetri GD, et al. Lancet. 2006;368(9544):1329–1338.
• Demetri GD, et al. Lancet. 2013;381(9863):295–302.
• Gardino A, et al. Mol Cell Oncol. 2018;5(3):e1435183.
• George S, et al. Oncologist. 2021;26(4):e639–e649.
• Gramza A, et al. Clin Cancer Res. 2009;15(24):7510–7518.
• Heinrich M, et al. J Clin Oncol. 2006;24(29):4764–4774.
• Heinrich M, et al. J Clin Oncol. 2008;26(33):5352–5359.
• Heinrich M, et al. Oral presentation at the Connective Tissue Oncology Society Annual Meeting 2018; 15 November 2018; Rome, Italy: #3027631.
• Heinrich M, et al. Lancet. 2020;21(7):935–946.
• IUPHAR/BPS Guide to Pharmacology. Ripretinib. Available at https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9175  Accessed September 2023.
• Jones R, et al. Eur J Cancer. 2021;145:132–142.
• Kang YK, et al. J Clin Oncol. 2021;39(28):3128–3139.
• Le Cesne A. Oral presentation at the ESMO Sarcoma and GIST Symposium 2022; 31 Jan – 2 Feb 2022; Virtual.
• Liegl B, et al. J Pathol. 2008;216(1):64–74.
• Patrikidou A, et al. Eur J Cancer. 2016;52:173–180.
• Raul C, et al. Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors. 2023. Available at https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-prognosis-of-gastrointestinal-stromal-tumors/print Accessed September 2023.
• Verweij J, et al. Lancet. 2004;364(9440):1127–1134.

ESMO 2023: Dr Serrano

• Bauer S, et al. ASCO Plenary Series: January 2023 Session.
• Bauer S, et al. Clin Cancer Res. 2021;27(23):6333–6342.
• ClinicalTrials.gov. NCT02164240. Last updated 14 June 2021. Available at https://clinicaltrials.gov/study/NCT02164240 Accessed October 2023.
• ClinicalTrials.gov. NCT03465722. Last updated 06 October 2022. Available at https://www.clinicaltrials.gov/study/NCT03465722 Accessed October 2023.
• ClinicalTrials.gov. NCT03673501. Last updated 06 January 2021. Available at https://www.clinicaltrials.gov/study/NCT03673501 Accessed October 2023.
• ClinicalTrials.gov. NCT05734105. Last updated 21 September 2023. Available at https://clinicaltrials.gov/ct2/show/NCT05734105 Accessed October 2023.
• George S, et al. 2023 ASCO Annual Meeting: TPS11582.
• Heitzer E, et al. Nat Rev Genet. 2019;20(2):71–88.
• Marquart J, et al. JAMA Oncol. 2018;4(8):1093–1098.
• Merker JD, et al. J Clin Oncol. 2018;36(16):1631–1641.
• Serrano C, et al. Clin Cancer Res. 2019;25(24):7287–7293.
• Serrano C, et al. 2022 ASCO Annual Meeting.
• Serrano C, et al. Ann Oncol. 2023;34(7):615–625.
• Serrano C, et al. Ann Oncol. 2023;34(7):615–625 Supplementary Material.
• Serrano C, Fletcher JA. Oncotarget. 2019;10(59):6286–6287.
• Serrano C, George S. Clin Cancer Res. 2020;26(19):5078–5085.

ESMO Sarcoma and Rare Cancers Congress 2023: Prof. Bauer

• Bauer S, et al. Int J Cancer. 2005;117:316–325
• Bauer S, et al. Clin Cancer Res. 2021;27(23):6333–6342
• Bauer S, et al. J Clin Oncol. 2022;40(34):3918–3928
• Bauer S, et al. Presented at ASCO Plenary Series; January 2023
• Bauer S, et al. Oral presentation at ASCO Plenary Series; January 2023
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934
• Casali P, et al. J Clin Oncol. 2017;35:1713–1720
• Corless CL, et al. J Clin Oncol. 2005;23(23):5357–5364
• Corless C, et al. Nat Rev Cancer. 2011;11(12):865–878
• Demetri GD, et al. Lancet. 2006;368:1329–1338
• Demetri GD, et al. Lancet. 2013;381(9863):295–302
• Evans EK, et al. Sci Transl Med. 2017;9(414):eaao1690
• Garner AP, et al. Clin Cancer Res. 2014;20(22):5745–5755
• GLIVEC® Summary of Product Characteristics
• Heinrich MC. ASCO; 2010: educational session
• Hornick JL, et al. Hum Pathol. 2007;38(5):679–687
• Mendel DB, et al. Clin Cancer Res. 2003;9(1):327–337
• Miettinen M, et al. Am J Surg Pathol. 2006;30(1):90–96
• Miettinen M, et al. Am J Surg Pathol. 2011;35(11):1712–1721
• Nemunaitis J, et al. Future Oncol. 2020;16(1):4251–4264
• QINLOCK® Summary of Product Characteristics
• Schwartz GK. J Clin Oncol. 2022;40(34):3903–3906
• Serrano C, et al. Presented at ASCO Annual Meeting; June 2022; Illinois, USA
• Smith BD, et al. Cancer Cell. 2019;35:738–751
• STIVARGA® Summary of Product Characteristics
• SUTENT® Summary of Product Characteristics
• Wardelmann E, et al. Lancet Oncol. 2005;6:249–251

ESMO Sarcoma and Rare Cancers Congress 2023: Doctor Benson

• Blay JY, et al. Lancet Oncol. 2020;21:923–934
• GLIVEC® Summary of Product Characteristics
• Radboud University Medical Center Nijmegen. Evaluation of the value of therapeutic drug monitoring to predict treatment outcome in terms of survival and toxicity in patients with solid tumors treated with imatinib, sunitinib andpazopanib. UK REC approval date: 23/02/2021
• Peña M, et al. Blood Adv. 2021;5(17):3344–3353
• Poster presentation at British Sarcoma Group Annual Conference, March 2023
• Serrano C, et al. Oral Presentation at the ESMO World Congress on Gastrointestinal Cancer; 1–4 July 2020; Virtual meeting
• STIVARGA® Summary of Product Characteristics
• Su Yin Lim, et al. Poster presented at ESMO Sarcoma and Rare Cancers Annual Congress; March 2023
• SUTENT® Summary of Product Characteristics
• von Mehren, et al. Poster presented at ESMO Virtual Congress; 16–21 September 2021

ESMO Sarcoma and Rare Cancers Congress 2023: Prof. Vincenzi

• Joensuu H, et al. Lancet Oncol. 2012;13(3):265–274
• Demetri GD, et al. J Natl Compr Canc Netw. 2010;8 Suppl 2(0 2):S1–44

ESMO 2022: Prof. Le Cesne

• Atiq MA, et al. Modern Pathol. 2021;34:95–10
• Ayvakyt (smpc). Amsterdam, NL; Blueprint Medicines. 2021
• Bauer S, et al. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR–21–1864
• Bauer S, et al. J Clin Oncol. 2022. DOI: 10.1200/JCO.22.00294
• Bauer S. et al. J Clin Oncol. 2022;JCO2200294. DOI: 10.200/JCO.22.00294
• Blanke CD, et al. J Clin Oncol. 2008;26(4):620–625
• Blay JY, et al. Lancet Oncol. 2015; 16(5):550–560
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934. Supplementary appendix
• Blay J-Y, et al. Poster presented at 17th Journées Annuelles Du GSF-GETO; June 29-July 1 2022
• Callejo et al. Target Oncol. 2021; 16 (4): 485-492. doi: 10.1007/s11523-021-00820-7
• Casali PG, et al. J Clin Oncol. 2017;35(15):1713–1720
• Casali PG, et al. Ann Oncol. 2021 Sep 21;S0923–7534(21)04480-X
• Casali PG, et al. Annals Oncol. 2021; 33(1):20–33
• Cassier PA, et al. Clin Cancer Res. 2012;15(18):4458–4464
• ClinicalTrials.gov. NCT0263876. Available at: https://clinicaltrials.gov/ct2/show/NCT02638766  Accessed January 2022
• ClinicalTrials.gov NCT05009927. Available at: https://clinicaltrials.gov/ct2/show/NCT05009927 Accessed September 2022
• Clinicaltrials.gov NCT03673501. Available at: https://clinicaltrials.gov/ct2/show/NCT03673501 Accessed September 2022
• Demetri GD, et al. Lancet. 2006;368:1329–1338
• Demetri GD, et al. Lancet. 2013; doi: 10.1016/S0140-6736(12)61857-1
• Demetri G, Albert CM, Tan DSW et al. Larotrectinib efficacy and safety in patients with TRK fusion sarcomas. CTOS 2019
• Drilon A, et al. N Engl J Med. 2018;378:731–739
• Glivec (SmPC). Dublin, IE : Novartis Europharm. 2021
• Grunewald S, et al. Cancer Dis. 2021; doi: 10.1158/2159-8290.CD-20-0487
• Heinrich MC, et al. JAMA Oncol. 2017;3(7):944–952
• Heinrich MC, et al. J Clin Oncol. 2017; doi: 10.1200/JCO.2017.35.15_suppl.11011
• Heinrich MC, et al. Lancet Oncol. 2020;21(7):935–946
• Hemming ML, et al. Ann Oncol. 2018;29:2037
• Hong D, et al. Cancer Disc. 2016; doi: 10.1158/2159-8290.CD–16–0050
• Janeway KA et al. Pediatr Blood Cancer. 2009;52(7):767–771
• Janku F, et al. J Clin Oncol. 2020;38:3294–3303
• Kang Y-K, et al. J Clin Oncol. 2021; 39(28):3128–3139
• Le Cesne A, et al. Lancet Oncol. 2010;11(10):942–949
• Lopes LF, et al. J Cell Mol Med. 2010;14:42
• Lostes-Bardaji MJ, et al. Ther Adv Med Oncol. 2021;13:1758835920986498
• MetaGIST. J Clin Oncol. 2010;28(7):1247–1253
• QINLOCK (SmPC). Amsterdam, NL: Deciphera Pharmaceuticals. 2021
• Qiu H et al. Oral Presentation Presented at ASCO Annual Meeting; June 3-7, 2022; Chicago,IL.
• Patrikidou A, et al. EJC. 2016;52:173–180
• Rivera et al, AACR 2021
• Salem ME, et al. Mol Cancer Res. 2018; doi: 10.1158/1541-7786.MCR–17–0735
• Shi SS, et al. Histopathology. 2017;71(4):553–561
• Smith BD, et al. Cancer cell. 2019;35(5):738–751.e9
• Vallilas C, et al. IJMS. 2021;22(2)493
• Vincenzi B, et al. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR-21-1665
• Wagner et al, JAMA Oncol. 2021
• Zalcberg JR. Ther Adv Gastroenterol. 2021;14:1–12

ESMO 2022: Prof. Italiano

• Blay JY, et al. Lancet Oncology. 2020; 21: 923–934
• Call et al. Clin Sarcoma Res. 2019;9:4
• Carbajal-López EB et al. J Cancer Educ. 2022;37(3):668–674.
• Casali PG, et al. J Clin Oncol. 2017;35(15):1713–1720
• Clinicaltrials.gov/NCT03963544
• Foo T, et al. Target Oncol. 2022;17(2):95–110.
• George S, et al. Eur J Cancer. 2021;155:236–244.
• Glivec (SmPC). Dublin, IE : Novartis Europharm. 2021
• Heinrich M, et al. Poster Presented at ASCO 2020 Virtual meeting; Data on File, 2022.
• Ma et al. Cancer Epidemiol Biomarkers Prev. 2015;24(1):298–302.
• QINLOCK (SmPC). Amsterdam, NL: Deciphera Pharmaceuticals
• Reichardt P, et al. Cancer. 2015;121(9):1405–1413.
• Poole CD, et al. Gastric Cancer. 2015;18(3):627–634.
• Schvartsman et al. Sci Rep. 2017;7(1):9519.
• Stivarga (SmPC). Leverkusen, DE : Bayer. 2021
• Sutent (SmPC). Bruxelles, BE : Pfizer Europe. 2021
• Xie et al. Adv Ther. 2019;36(8):1986–1998.

ESMO 2022: Prof. Reichardt

• Blay et al. Lancet Oncol. 2020
• Demetri GD et al. Lancet. 2006;3681329–1338
• Demetri GD, Reichardt P, Kang YK, et al. Lancet. 2013
• European Medicines Agency (EMA) assessment report, EMA/CHMP/55164/2021
• Kang Y-K et al. Lancet Oncology. 2014
• QINLOCK [summary of product characteristics]. Amsterdam, NL: Deciphera Pharmaceuticals (Netherlands) B.V.; 2021.
• Reichardt P et al. Ann Oncol. 2012
• Reichardt P et al. CTOS 2012

ESMO Sarcoma and GIST Symposium 2022: Prof. Gronchi

• An HJ, et al. Ann Surg Oncol. 2013;20(13):4212–4218.
• Bauer S, et al. Eur J Surg Oncol. 2014;40:412–419.
• Blanke CD, et al. J Clin Oncol. 2008;26(4):626–632.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• DeMatteo RP, et al. Ann Surg. 2007;245(3):347–352.
• Demetri GD, et al. Lancet. 2006;368:1329–1338.
• Demetri GD, et al. Lancet. 2013;381:295–302.
• Du CY, et al. Eur J Cancer. 2014;50:1772–1778.
• Fairweather M, et al. Ann Surg. 2018;268(2):296–302.
• Fiore M, et al. Eur J Surg Oncol. 2009;35(7):739–745.
• Gronchi A, et al. Ann Surg. 2007;245(3):341–346.
• Gronchi A, et al. Ann Surg Oncol. 2012;19:3361–3367.
• Gronchi A, et al. Ann Surg Oncol. 2012;19:1051–1055.
• Haller F, et al. Ann Surg Oncol. 2007;14:526–532.
• Heinrich MC, et al. Lancet Oncol. 2020;21:935–946.
• Joensuu H, et al. Lancet Oncol. 2012;13:265–274.
• Le Cesne A, et al. Lancet Oncol. 2010;11(10):942–949.
• Nannini M, et al. J Med Genet. 2013;50:653–661.
• Park SJ, et al. Ann Surg Oncol. 2014;21(13):4211–4217.
• QINLOCK^® SmPC. 2021.
• Raut CP, et al. J Clin Oncol. 2006;24(15):2325–2331.
• Rubiò-Casadevall J, et al. Ann Surg Oncol. 2015;22(9):2948–2957.
• Rutkowski P, et al. Ann Surg Oncol. 2013;20:2937–2943.
• Sharma AK, et al. Clin Cancer Res. 2021;27:5334–5342.
• Stivarga^® SmPC. 2021.
• Sutent^® SmPC. 2021.
• van Glabbeke M, et al. J Clin Oncol. 2005;23(24):5795–5804.
• Verweij J, et al. Lancet. 2004;364(9440):1127–1134.

ESMO Sarcoma and GIST Symposium 2022: Dr Serrano

• Evans EK, et al. Sci Transl Med. 2017;1;9(414):eaao1690.
• Gramza AW, et al. Clin Cancer Res. 2009;15(24):7510–7518.
• Lopes LF, et al. J Cell Mol Med. 2010;14(1–2):43–50.
• Mariño-Enríquez A, Bovée J. Surg Pathol Clin. 2016;9(3):457–473.
• Nannini M, et al. BMC Cancer. 2014; doi: 10.1186/1471-2407-14-685.
• Oppelt PJ, et al. J Gastrointest Oncol. 2017;8(3):466–473.
• Ordog T, et al. Stem Cells Transl Med. 2015;4(7):702–707.
• Serrano C, George S. Ther Adv Med Oncol. 2014;6(3):115–127.
• Serrano C, et al. J Clin Oncol. 2015;33(22):e93–e96.
• Serrano C, et al. Br J Cancer. 2019;120(6):612–620.
• Serrano C, George S. Clin Cancer Res. 2020;26:5078–5085.
• Serrano C, et al. BMC Cancer. 2020; doi: 10.1186/s12885-020-6597-x.
• Serrano C. Curr Op Oncol. 2021;33:323–328.
• Smith BD, et al. Cancer Cell. 2019;35(5):738–751.e9.
• Wozniak A, et al. Clin Can Res. 2014;20(23):6105–6116.
• Yan W, et al. Chin J Cancer. 2016; doi: 10.1186/s40880-016-0131-1.

ESMO Sarcoma and GIST Symposium 2022: Prof. Le Cesne

• Atiq MA, et al. Modern Pathol. 2021;34:95–103.
• Bauer S, et al. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR-21-1864.
• Blanke CD, et al. J Clin Oncol. 2008;26(4):620–625.
• Blay JY, et al. Lancet Oncol. 2015;16(5):550–560.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934. Supplementary appendix.
• Callejo A, et al. Target Oncol. 2021;16 (4):485–492.
• Casali PG, et al. J Clin Oncol. 2017;35(15):1713–1720.
• Casali PG, et al. Ann Oncol. 2022;33:20–33.
• Cassier PA, et al. Clin Cancer Res. 2012;15(18):4458–4464.
• ClinicalTrials.gov. NCT02638766. Available at https://clinicaltrials.gov/ct2/show/NCT02638766. Accessed January 2022.
• Deciphera Press Release. November 2021.
• Demetri GD, et al. Lancet. 2006;368:1329–1338.
• Demetri GD, et al. J Clin Oncol. 2009;27(25):4188–4196.
• Demetri GD, et al. Presented at European Society for Medical Oncology; 27 September – 1 October 2013; Amsterdam, Netherlands.
• Demetri GD, et al. Lancet. 2013; doi: 10.1016/S0140-6736(12)61857-1.
• Demetri G, et al. Presented at Connective Tissue Oncology Society; 15 November 2019; Tokyo, Japan.
• Drilon A, et al. N Engl J Med. 2018;378:731–739.
• Grunewald S, et al. Cancer Dis. 2021; doi: 10.1158/2159-8290.CD-20-0487.
• Heinrich MC, et al. JAMA Oncol. 2017;3(7):944–952.
• Heinrich MC, et al. J Clin Oncol. 2017; doi: 10.1200/JCO.2017.35.15_suppl.11011.
• Heinrich MC, et al. Lancet Oncol. 2020;21(7):935–946.
• Hong D, et al. Cancer Disc. 2016; doi: 10.1158/2159-8290.CD-16-0050.
• Houk BE, et al. Cancer Chemother Pharmacol. 2010;66(2):357–371.
• Kang YK, et al. J Clin Oncol. 2021;39(26):2903–2913.
• Le Cesne A, et al. Lancet Oncol. 2010;11(10):942–949.
• Lostes-Bardaji MJ, et al. Ther Adv Med Oncol. 2021;13:1758835920986498.
• MetaGIST. J Clin Oncol. 2010;28(7):1247–1253.
• Patrikidou A, et al. EJC. 2016;52:173–180.
• Salem ME, et al. Mol Cancer Res. 2018; doi: 10.1158/1541-7786.MCR-17-0735.
• Shi SS, et al. Histopathology. 2017;71(4):553–561.
• Vallilas C, et al. IJMS. 2021;22(2)493.
• Verweij J, et al. Lancet. 2014;364(9440):1127–1134.
• Vincenzi B, et al. Clin Cancer Res. 2021; doi: 10.1158/1078-0432.CCR-21-1665.
• von Mehren M, et al. Oral Presentation at European Society for Medical Oncology; 27 September – 1 October 2019; Barcelona, Spain.
• Zalcberg JR, et al. Oncologist. 2021; doi: 10.1002/onco.13917.
• Zalcberg JR. Ther Adv Gastroenterol. 2021;14:1–12.

ESMO 2021: Prof. Reichardt

• Akahoshi K, et al. World J Gastroenterol. 2018;24(26):2806–2817.
• Antonescu CR, et al. Clin Cancer Res. 2005;11(11):4182–4190.
• Astolfi A, et al. Int J Mol Sci. 2020;21(9):3313.
• Ayvakit^TM Prescribing Information. June 2021.
• Babaei MA, et al. Drug Des Devel Ther. 2016;10:2443–2459.
• Call J, et al. BMC Cancer. 2012;12:90.
• Casali PG, et al. Annal Oncol. 2018;29(Suppl 4):iv68–iv78.
• Casali PG, et al. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019:895–906.
• Corless CL. Mod Pathol. 2014;27(Suppl 1):S1–S16.
• DeMatteo RP, et al. Ann Surg. 2000;231(1):51–58.
• Demetri GD, et al. N Engl J Med. 2002;347(7):472–480.
• Demetri GD, et al. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1–41; quiz S42–S44.
• Demetri GD. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 9th ed; Philadelphia, PA: Wolters Kluwer; 2011:1060–1073.
• Duffaud F, Le Cesne A. F1000Res. 2017; doi: 10.12688/f1000research.11118.1.
• Edmonson JH, et al. Cancer Invest. 2002;20(5–6):605–612.
• Foo WC, et al. Clin Med Insights Pathol. 2012;5:23–33.
• George S, et al. Poster presented at American Society of Clinical Oncology; 1–5 June 2018; Chicago, IL; abstract #11511.
• Glivec^® Prescribing Information. August 2020.
• Gramza AW, et al. Clin Cancer Res. 2009;15(24):7510–7518.
• Heinrich MC, et al. Science. 2003;299(5607):708–710.
• Hemming ML, et al. Ann Oncol. 2018;29(10):2037–2045.
• Hirota S, et al. Science. 1998;279(5350):577–580.
• Joensuu H, et al. Lancet Oncol. 2012;13(3):265–274.
• Joensuu H, et al. JAMA Oncol. 2020;6:1241–1246.
• Laurini JA, et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor (GIST). College of American Pathologists website. Available at https://documents.cap.org/protocols/cp-gist-2017-v4001.pdf. Accessed August 2021.
• Lennartsson J, et al. Physiol Rev. 2012;92(4):1619–1649.
• Li K, et al. Oncotarget. 2017;8(36):60589–60604.
• Lopes LF, Bacchi CE. J Cell Mol Med. 2010;14(1–2):42–50.
• Lostes-Bardaji MJ, et al. Ther Adv Med Oncol. 2021; doi: 10.1177/1758835920986498.
• Mazur MT, Clark HB. Am J Surg Pathol. 1983;7(6):507–519.
• MedlinePlus. Neurofibromatosis type 1. Available at https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1. Accessed August 2021.
• Miettinen M, Lasota J. Semin Diagn Pathol. 2006;23(2):70–83.
• NCCN guidelines. Gastrointestinal stromal tumors (GIST). Available at https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1507. Accessed August 2021.
• Oppelt PJ, et al. J Gastrointest Oncol. 2017;8(3):466–473.
• Ordog T, et al. Stem Cells Transl Med. 2015;4(7):702–707.
• Parab TM, et al. J Gastrointest Oncol. 2019;10(1):144–154.
• Patel N, Benipal B. Cureus. 2019; doi: 10.7759/cureus.4120.
• QINLOCK^® Prescribing Information. June 2021.
• Quek R, George S. Hematol Oncol Clin North Am. 2009;23(1):69–78.
• Rammohan A, et al. World J Gastrointest Oncol. 2012;5(6):102–112.
• Raut CP, et al. JAMA Oncol. 2018;4(12):e184060.
• Ricci R. Hered Cancer Clin Pract. 2016; doi: 10.1186/s13053-016-0055-4.
• Smith BD, et al. Cancer Cell. 2019;35(5):738–751.
• Soreide K, et al. Cancer Epidemiol. 2016;40:39–46.
• Stivarga^® Prescribing Information. December 2020.
• Sutent^® Prescribing Information. August 2020.
• TudorRose Consulting Pty Ltd. Data on file. Orphan Drug Designation Application Australian Specific Annex to EU Orphan Drug Application 08 June 2017; Qinlock (ripretinib) 50mg tablets; 2019.
• UpToDate Online. Morgan J, et al. Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumours. Available at https://www.uptodate.com/contents/epidemiology-classification-clinical-presentation-prognostic-features-and-diagnostic-work-up-of-gastrointestinal-stromal-tumors-gist? Accessed August 2021.
• von Mehren M, et al. J Clin Oncol. 2018;36(2):136–143.
• Wagner AJ, et al. Mod Pathol. 2013;26(2):289–294.
• Wang Y, Call J. Curr Cancer Drug Targets. 2019;19(9):688–697.
• Yan W, et al. Chin J Cancer. 2016;35(1):68.
• Zhao X, Yue C. J Gastrointest Oncol. 2012;3(3):189–208.

ESMO 2021: Prof. Bauer

• Bauer S, et al. Int J Cancer. 2005;117:316–325.
• Bauer S, et al. Eur J Surg Oncol. 2014;40(4):412–419.
• Bauer S, et al. Clin Cancer Res. 2021;27(23):6333–6342.
• Blanke CD, et al. J Clin Oncol. 2008;26(4):626–632.
• Casali PG, et al. J Clin Oncol. 2017;35:1713–1720.
• Casali PG, et al. Ann Oncol. 2022;33(1):20–33.
• Corless CL, et al. J Clin Oncol. 2005;23(23):5357–5364.
• Debiec-Rychter, et al. Eur J Cancer. 2006;42(8):1093–1103.
• Demetri GD, et al. Lancet. 2006;368:1329–1338.
• Demetri GD, et al. Lancet. 2013;381(9863):295–302.
• Garner AP, et al. Clin Cancer Res. 2014;20(22):5745–5755.
• Heinrich MC. Presented at American Society of Clinical Oncology; 4–8 June 2010; Chicago, Illinois.
• Hornick JL, Fletcher CDM. Hum Pathol. 2007;38(5):679–687.
• Jones RL, et al. Eur J Cancer. 2021;145:132–142.
• MetaGIST. J Clin Oncol. 2010;28(7):1247–1253.
• Miettinen M, et al. Am J Surg Pathol. 2006;30(1):90–96.
• Miettinen M, et al. Am J Surg Pathol. 2011;35(11):1712–1721.
• Mühlenberg T, et al. Mol Cancer Ther. 2019; doi: 0.1158/1535-7163.MCT-18-1224.
• Serrano C, et al. J Clin Oncol. 2015;33(22):e93–96.
• Verweij J, et al. Lancet. 2004;364:1127–1134.
• Wardelmann E, et al. Lancet Oncol. 2005;6:249–251.

ESMO 2021: Prof. Blay

• Ayvakit^TM SmPC. 2021.
• Blay JY, et al. Lancet Oncol. 2020;21(7):923–934.
• ClinicalTrials.gov. NCT01738139. Available at https://clinicaltrials.gov/ct2/show/NCT01738139. Accessed August 2021.
• ClinicalTrials.gov. NCT02216578. Available at https://clinicaltrials.gov/ct2/show/NCT02216578. Accessed August 2021.
• ClinicalTrials.gov. NCT04106024. Available at https://clinicaltrials.gov/ct2/show/NCT04106024. Accessed August 2021.
• ClinicalTrials.gov. NCT04193553. Available at https://clinicaltrials.gov/ct2/show/NCT04193553. Accessed August 2021.
• Cogent. Programs. Available at https://www.cogentbio.com/programs/. Accessed August 2021.
• Cocco E, et al. Nat Rev Clin Oncol. 2018;15:731–747.
• Doebele RC, et al. Cancer Disc. 2015;5:1049–1057.
• Drilon A, et al. Cancer Discov. 2017;7(9);963–972.
• Drilon A, et al. N Engl J Med. 2018;378:731–739.
• Drilon A. Ann Oncol. 2019;30(Suppl 8):viii23–viii30.
• Drilon A, et al. Presented at American Society of Clinical Oncology; 31 May – 4 June 2019; abstract #2006.
• Gelderblom H, et al. Poster presented at Connective Tissue Oncology Society; 18–21 November 2020; Virtual.
• George S, et al. Oncologist. 2021;26(4):e639–e649.
• Grunewald S, et. Cancer Discov. 2021;11(1):108–125.
• Heinrich MC, et al. Presented at Connective Tissue Oncology Society; 15 November 2019; Tokyo, Japan.
• Heinrich MC, et al. Lancet Oncol. 2020;21:935–946.
• Hong DS, et al. Lancet Oncol. 2020;21(4):531–540.
• Hyman DM, et al. Presented at American Society of Clinical Oncology; 2–6 June 2017; Chicago, IL; LBA2501.
• Jones RL, et al. Eur J Cancer. 2021;145:132–142.
• Jones RL, et al. Presented at European Society for Medical Oncology; 19–21 September 2020; Virtual.
• Kang YK, et al. J Clin Oncol. 2021;39(28):3128–3139.
• Nemunaitis J, et al. Future Oncol. 2020;16(1):4251–4264.
• Neppala P, et al. Cancer Metastasis Rev. 2019;38(3):525–535.
• Rozlytrek SmPC. 2020.
• Schöffski P, et al. Eur J Cancer. 2020;134:62–74.
• Smith BD, et al. Cancer Cell. 2019;35:738–751.
• VITRAKVI Prescribing Information. November 2018.
• VITRAKVI SmPC. 2021.
• von Mehren M, et al. BMC Cancer. 2021;21:291.
• von Mehren M, et al. Poster presented at European Society for Medical Oncology; 16–21 September 2021; Virtual.
• Zalcberg J, et al. Presented at European Society for Medical Oncology; 19–21 September 2020; Virtual.

QINLOCK Summary of Product Characteristics